Baxdrostat Shows Dramatic Blood Pressure Reduction in Treatment-Resistant Hypertension Trial
Key Insights
A phase II trial of 248 patients demonstrated that baxdrostat, a novel aldosterone synthesis inhibitor, reduced systolic blood pressure by 20.3 mm Hg in treatment-resistant hypertension patients taking the highest 2mg dose.
The drug showed an 11-point difference compared to placebo, representing a rarely achieved magnitude of blood pressure reduction for a single medication in this challenging patient population.
Baxdrostat works by blocking aldosterone production, targeting the hormonal mechanism underlying treatment resistance that affects up to 12 million Americans and potentially 500,000 people in the UK.
A groundbreaking phase II trial has demonstrated that baxdrostat, a first-in-class aldosterone synthesis inhibitor, achieved dramatic blood pressure reductions in patients with treatment-resistant hypertension. The study, published in The New England Journal of Medicine and presented at the American Heart Association Scientific Sessions conference, represents the first successful development and testing of this long-sought new class of drugs for resistant hypertension.
Trial Design and Patient Population
The 12-week, placebo-controlled trial enrolled 248 patients whose blood pressure remained uncontrolled despite taking three or more antihypertensive medications. Participants received once-daily baxdrostat at doses of 2mg, 1mg, or 0.5mg, or placebo, in addition to their existing medications. The study was funded by CinCor Pharma (search), the drug's manufacturer.
Dose-Dependent Efficacy Results
The trial demonstrated clear dose-dependent effects, with patients receiving higher doses experiencing greater blood pressure reductions. The highest dose group (2mg) achieved a remarkable 20.3 mm Hg reduction in systolic blood pressure, compared to 12.1 mm Hg, 7.5 mm Hg, and 9.4 mm Hg reductions in the 0.5mg, 1mg, and placebo groups, respectively.
The 11-point difference between the highest dose group and placebo represents a magnitude of blood pressure reduction rarely seen with any single drug, according to the researchers. The study was terminated at 12 weeks after reaching the required level of effectiveness at the three-month mark.
Mechanism of Action and Clinical Significance
Baxdrostat works by blocking the enzyme that produces aldosterone, a key hormonal contributor to hypertension that regulates salt retention in the body. The drug successfully suppressed both blood and urine levels of aldosterone, demonstrating that treatment-resistant hypertension is partly due to excess production of this hormone.
Professor Morris Brown, co-senior author and Professor of Endocrine Hypertension at Queen Mary University of London, explained the drug's targeted approach: "The effectiveness of older drugs in individual patients can vary substantially, whereas a hallmark of this new class is that it can be predicted to work well in the patients whose aldosterone hormone has made them resistant to older treatments."
Addressing a Significant Unmet Need
Treatment-resistant hypertension affects up to 12 million Americans and potentially more than 500,000 people in the UK. This condition occurs in 5-10% of hypertensive patients, often due to gene mutations in the adrenal glands that result in excessive aldosterone production.
Dr. Aseem Desai, a cardiac electrophysiologist affiliated with Providence Mission Hospital, emphasized the clinical reality: "There is a small subset of patients that have truly treatment-resistant hypertension. They're doing everything they possibly can, and their numbers are still running high."
Safety Profile and Tolerability
The trial demonstrated a favorable safety profile, with only two patients experiencing adverse reactions connected to the drug. Both cases involved increased potassium levels that did not resolve when treatment was stopped and restarted. Importantly, unlike other treatment options, baxdrostat did not increase cortisol levels, avoiding additional adverse effects associated with cortisol elevation.
Clinical Practice Implications
Dr. Sameer Mehta, an interventional cardiologist and president of Denver Heart, highlighted the clinical advantage: "From a clinical practice standpoint, the challenge of when you get to fourth and fifth-line drug agents is: number one, the bang for the buck is often fairly low; but number two, you're often dealing with drugs with a fairly pronounced side effect profile."
He contrasted baxdrostat's profile with existing medications like spironolactone and clonidine, which can cause a wide range of side effects, calling the level of blood pressure reduction "dramatic."
Development History and Future Outlook
The obstacle to developing such a drug has historically been matching the drug's target enzyme, which makes aldosterone, with another enzyme that produces the essential steroid hormone cortisol. Professor Brown has been personally involved in the drug's development for over 10 years, working closely with pharmaceutical firms and start-ups that have licensed the technology.
While experts express optimism about the results, the medication must complete multiple rounds of further testing before consideration for FDA approval. The trial results provide hope for patients who have exhausted traditional treatment options, offering a more selective approach with fewer side effects than current fourth and fifth-line therapies.